# Celebrex Total Knee Arthroplasty Study

> **NCT00359151** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 22 (actual)

## Conditions studied

- Osteoarthritis
- Pain

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00359151
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** This study was terminated early due to slow enrollment.
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00359151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00359151, "Celebrex Total Knee Arthroplasty Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00359151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*